GUTS
Fractyl Health, Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Last price
0.78
▲ 0.10 (14.14%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Tool
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
0.68
Prev close
0.69
Day high
0.81
Day low
0.69
Volume
3.37M
Market cap
$124.16M
P/E (TTM)
—
52W range
0.38 – 2.45
Day trading desk
Gap from prior close
-0.03%
Prior close 0.69
VWAP
0.77
+1.11% from price
Relative volume
2.08×
Unusually busy
Session range
22.17%
0.66 – 0.81
Position in range
81%
Near session high
ATR (14D)
0.05
6.48% of price
Prior day high
0.71
PDH
Prior day low
0.67
PDL
Bid / ask spread
—
Quote not published
Session volume
3.36M
Avg 1.62M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+14.71%
+16.1%
1M
+3.04%
-0.7%
3M
-15.22%
-18.3%
6M
+66.67%
+55.6%
YTD
-64.55%
-76.8%
1Y
-20.41%
-40.4%
3Y
—
-74.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on GUTS open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
2.15M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 12, 26 | ROYAN AJAY G. Director |
BUY | 23.00K | $19.60K | Direct |
| Jun 10, 26 | BRADLEY WILLIAM C Director |
BUY | 68.49K | $50.33K | Direct |
| Jun 10, 26 | SHEFFIELD IAN Director |
BUY | 35.00K | $25.53K | Direct |
| Jun 10, 26 | RAJAGOPALAN HARITH M.D., PH.D. Chief Executive Officer |
BUY | 25.00K | $18.25K | Direct |
| Jun 8, 26 | SMITH WEBER LARA Chief Financial Officer |
BUY | 20.00K | $13.71K | Direct |
| Dec 4, 25 | RAJAGOPALAN HARITH M.D., PH.D. Chief Executive Officer |
BUY | 10.42K | $20.00K | Direct |
| Mar 14, 25 | ROYAN AJAY G. Director and Beneficial Owner of more than 10% of a Class of Security |
BUY | 17.90K | $22.98K | Direct |
| Mar 14, 25 | BARNES KELLY ANN Director |
BUY | 31.00K | $40.21K | Direct |
| Mar 13, 25 | BRADLEY WILLIAM C Director |
BUY | 16.13K | $20.36K | Direct |
| Mar 13, 25 | SCHULMAN AMY W. Director |
BUY | 8.55K | $9.96K | Direct |
| Mar 13, 25 | CONAWAY SAMUEL Director |
BUY | 8.55K | $9.96K | Direct |
| Jan 31, 25 | CAPLAN JAY DAVID President |
SELL | 43.82K | $82.27K | Direct |
| Jan 31, 25 | RAJAGOPALAN HARITH M.D., PH.D. Chief Executive Officer |
SELL | 111.92K | $206.00K | Direct |
| Jan 31, 25 | CAPLAN JAY DAVID President |
CONVERSION | 43.82K | $74.49K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BARNES KELLY ANN |
Director | 31.00K | Purchase |
BRADLEY WILLIAM C |
Director | 84.62K | Purchase |
CAPLAN JAY DAVID |
President | 631.16K | Sale |
CONAWAY SAMUEL |
Director | 8.55K | Purchase |
RAJAGOPALAN HARITH M.D., PH.D. |
Chief Executive Officer | 1.14M | Purchase |
ROYAN AJAY G. |
Director | 6.45M | Purchase |
SCHULMAN AMY W. |
Director | 8.55K | Purchase |
SHEFFIELD IAN |
Director | 35.00K | Purchase |
SMITH WEBER LARA |
Chief Financial Officer | 20.00K | Purchase |
Fundamentals
Market cap$124.16M
Enterprise value$137.76M
Revenue (TTM)—
Gross profit—
EBITDA$-84.77M
Net income$-105.65M
EPS (TTM)$-0.91
Free cash flow$-48.36M
Total cash$47.14M
Total debt$60.74M
Book value / share$-0.01
Shares outstanding159.18M
Float145.87M
Short % of float2.11%
Dividend yield—
Beta (5Y)2.32
Valuation & profitability ratios
Trailing P/E—
Forward P/E-1.78
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA-1.63
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity—
Return on assets-74.57%
Debt / equity—
Current ratio3.15
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $93.00K | $120.00K | $0 | -100.0% |
| Operating revenue | $0 | $93.00K | $120.00K | $0 | -100.0% |
| Cost of revenue | $0 | $50.00K | $77.00K | $0 | -100.0% |
| Gross profit | $0 | $43.00K | $43.00K | $0 | -100.0% |
| Research & development | $74.54M | $70.47M | $38.04M | $34.35M | +5.8% |
| Selling, general & admin | $22.28M | $23.10M | $12.84M | $15.03M | -3.6% |
| Total operating expense | $96.82M | $93.57M | $50.88M | $49.38M | +3.5% |
| Operating income | -$96.82M | -$93.53M | -$50.84M | -$49.38M | -3.5% |
| Net interest income | $1.54M | $4.15M | $1.26M | $797.00K | -62.9% |
| Pre-tax income | -$140.95M | -$68.69M | -$77.09M | -$46.45M | -105.2% |
| Net income | -$140.95M | -$68.69M | -$77.09M | -$46.45M | -105.2% |
| Net income to common | -$140.95M | -$70.43M | -$94.27M | -$63.63M | -100.1% |
| Basic EPS | -0.92 | -1.62 | -1.98 | -1.34 | +43.3% |
| Diluted EPS | -0.92 | -1.62 | -1.98 | -1.34 | +43.3% |
| EBIT | -$96.82M | -$93.53M | -$50.84M | -$49.38M | -3.5% |
| EBITDA | -$95.69M | -$92.85M | -$50.55M | -$48.93M | -3.1% |
| Basic shares | 153.37M | 43.54M | 47.61M | 47.61M | +252.2% |
| Diluted shares | 153.37M | 43.54M | 47.61M | 82.43M | +252.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $81.54M | $67.46M | $33.21M | $49.27M | — | +20.9% |
| Cash & short-term investments | $81.54M | $67.46M | $33.21M | $49.27M | — | +20.9% |
| Accounts receivable | — | $0 | $22.00K | $0 | — | — |
| Inventory | $0 | $73.00K | $73.00K | $0 | — | -100.0% |
| Total current assets | $87.58M | $71.76M | $35.65M | $51.63M | — | +22.0% |
| Property, plant & equipment | $29.23M | $31.39M | $30.77M | $1.65M | — | -6.9% |
| Total assets | $121.40M | $108.08M | $76.21M | $60.96M | — | +12.3% |
| Total current liabilities | $18.33M | $19.77M | $11.19M | $7.31M | — | -7.3% |
| Current debt | — | — | — | — | $15.72M | — |
| Long-term debt | $30.59M | $30.16M | $55.15M | $17.76M | — | +1.4% |
| Total debt | $61.65M | $62.50M | $86.39M | $19.48M | — | -1.4% |
| Total liabilities | $111.94M | $79.65M | $401.27M | $313.27M | — | +40.5% |
| Retained earnings | -$556.26M | -$415.31M | -$346.62M | -$269.52M | — | -33.9% |
| Shareholder equity | $9.46M | $28.42M | -$325.06M | -$252.32M | — | -66.7% |
| Working capital | $69.25M | $51.99M | $24.46M | $44.32M | — | +33.2% |
| Net tangible assets | $9.46M | $28.42M | -$325.06M | -$252.32M | — | -66.7% |
| Shares issued | 153.37M | 48.76M | 47.90M | 47.55M | — | +214.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$140.95M | -$68.69M | -$77.09M | -$46.45M | -105.2% |
| Depreciation & amortisation | $1.13M | $677.00K | $286.00K | $452.00K | +66.8% |
| Stock-based compensation | $6.68M | $14.43M | $4.30M | $3.14M | -53.7% |
| Change in working capital | -$395.00K | $9.59M | $989.00K | -$1.24M | -104.1% |
| Operating cash flow | -$90.33M | -$65.52M | -$42.82M | -$46.24M | -37.9% |
| Capital expenditure | -$557.00K | -$1.76M | -$359.00K | -$56.00K | +68.4% |
| Investing cash flow | -$557.00K | -$1.76M | -$359.00K | -$56.00K | +68.4% |
| Financing cash flow | $104.96M | $101.23M | $27.44M | $4.35M | +3.7% |
| Free cash flow | -$90.89M | -$67.29M | -$43.18M | -$46.30M | -35.1% |
| End cash position | $85.80M | $71.72M | $37.78M | $53.52M | +19.6% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Cost of revenue | — | $0 | $0 | $0 | $0 | $0 | — |
| Gross profit | — | $0 | $0 | $0 | $0 | $3.00K | — |
| Research & development | $15.60M | $16.49M | $17.46M | $21.15M | $19.43M | — | -5.4% |
| Selling, general & admin | $5.22M | $6.79M | $5.24M | $4.93M | $5.32M | — | -23.1% |
| Total operating expense | $20.82M | $23.28M | $22.69M | $26.08M | $24.76M | — | -10.6% |
| Operating income | -$20.82M | -$23.28M | -$22.69M | -$26.08M | -$24.76M | — | +10.6% |
| Net interest income | $593.00K | $645.00K | $166.00K | $226.00K | $503.00K | — | -8.1% |
| Pre-tax income | $9.22M | -$43.73M | -$45.60M | -$27.89M | -$23.73M | — | +121.1% |
| Net income | $9.22M | -$43.73M | -$45.60M | -$27.89M | -$23.73M | — | +121.1% |
| Net income to common | $9.22M | -$43.73M | -$45.60M | -$27.89M | -$23.73M | — | +121.1% |
| Basic EPS | 0.06 | -0.29 | -0.71 | -0.56 | -0.49 | — | +121.0% |
| Diluted EPS | 0.06 | -0.29 | -0.71 | -0.56 | -0.49 | — | +121.0% |
| EBIT | -$20.82M | -$23.28M | -$22.69M | -$26.08M | -$24.76M | — | +10.6% |
| EBITDA | -$20.54M | -$23.00M | -$22.40M | -$25.81M | -$24.47M | — | +10.7% |
| Basic shares | 158.49M | 153.37M | 64.65M | 49.92M | 48.92M | — | +3.3% |
| Diluted shares | 158.49M | 153.37M | 64.65M | 49.92M | 48.92M | — | +3.3% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $63.17M | $81.54M | $77.66M | $22.29M | $42.11M | — | -22.5% |
| Cash & short-term investments | $63.17M | $81.54M | $77.66M | $22.29M | $42.11M | — | -22.5% |
| Accounts receivable | — | — | — | — | — | $0 | — |
| Inventory | — | $0 | $0 | $0 | $0 | $73.00K | — |
| Total current assets | $65.92M | $87.58M | $79.70M | $26.69M | $47.05M | — | -24.7% |
| Property, plant & equipment | $28.53M | $29.23M | $29.92M | $30.61M | $31.17M | — | -2.4% |
| Total assets | $99.39M | $121.40M | $114.27M | $62.01M | $83.04M | — | -18.1% |
| Total current liabilities | $15.41M | $18.33M | $18.68M | $21.83M | $18.80M | — | -15.9% |
| Long-term debt | $30.14M | $30.59M | $30.77M | $29.98M | $29.39M | — | -1.5% |
| Total debt | $60.82M | $61.65M | $62.18M | $61.72M | $61.42M | — | -1.3% |
| Total liabilities | $78.01M | $111.94M | $117.45M | $80.22M | $76.67M | — | -30.3% |
| Retained earnings | -$547.05M | -$556.26M | -$512.54M | -$466.93M | -$439.05M | — | +1.7% |
| Shareholder equity | $21.38M | $9.46M | -$3.18M | -$18.21M | $6.38M | — | +126.0% |
| Working capital | $50.51M | $69.25M | $61.02M | $4.86M | $28.24M | — | -27.1% |
| Net tangible assets | $21.38M | $9.46M | -$3.18M | -$18.21M | $6.38M | — | +126.0% |
| Shares issued | 158.65M | 153.37M | 132.22M | 49.92M | 48.92M | — | +3.4% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | $9.22M | -$43.73M | -$45.60M | -$27.89M | -$23.73M | — | +121.1% |
| Depreciation & amortisation | $281.00K | $279.00K | $290.00K | $270.00K | $290.00K | — | +0.7% |
| Stock-based compensation | $2.53M | $1.85M | $1.64M | $1.78M | $1.41M | — | +36.4% |
| Change in working capital | -$4.49M | -$218.00K | -$1.50M | $3.22M | -$1.90M | — | -1,960.1% |
| Operating cash flow | -$22.48M | -$21.34M | -$22.71M | -$21.20M | -$25.08M | — | -5.3% |
| Capital expenditure | — | -$3.00K | -$8.00K | -$98.00K | -$448.00K | -$233.00K | — |
| Investing cash flow | $0 | -$3.00K | -$8.00K | -$98.00K | -$448.00K | — | +100.0% |
| Financing cash flow | $4.11M | $25.22M | $78.09M | $1.48M | $171.00K | — | -83.7% |
| Free cash flow | -$22.48M | -$21.34M | -$22.72M | -$21.30M | -$25.53M | — | -5.3% |
| End cash position | $67.42M | $85.80M | $81.91M | $26.55M | $46.36M | — | -21.4% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.14 | -0.12 | +13.9% |
| Dec 2025 | -0.18 | -0.07 | +61.1% |
| Sep 2025 | -0.30 | -0.71 | -139.3% |
| Jun 2025 | -0.36 | -0.57 | -58.3% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.12 | 6 | $0 | 0.0% |
| Next quarter | -0.11 | 4 | $0 | 0.0% |
| Current year | -0.33 | 4 | $0 | 0.0% |
| Next year | -0.44 | 6 | $22.38M | 0.0% |
Analyst targets & ownership
Mean target$5.03
High target$8.00
Low target$2.00
Implied upside543.65%
Analyst count6
ConsensusSTRONG BUY
Strong buy / Buy0 / 6
Hold1
Sell / Strong sell0 / 0
Held by insiders1.35%
Held by institutions51.51%
Institutions holding91
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
0.69
+12.63% from price
SMA 20
0.70
+11.70% from price
SMA 50
0.76
+2.77% from price
SMA 100
0.72
+8.52% from price
SMA 200
0.99
-21.38% from price
EMA 12
0.71
+10.91% from price
EMA 26
0.72
+8.93% from price
EMA 50
0.73
+6.51% from price
RSI (14)
58.2
Neutral
MACD (12,26,9)
-0.01
Hist 0.01
ATR (14)
0.05
6.49% of price
Realised vol 30D
80.4%
Annualised
Bollinger upper
0.77
20, 2σ
Bollinger lower
0.63
20, 2σ
50 / 200 cross
Death
0.76 vs 0.99
Trend bias
Below 200
-21.38%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
2.17
More volatile than market
Correlation to SPY
0.24
Largely independent
Realised vol 30D
80.4%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-83.4%
Peak to trough
Max drawdown 5Y
-96.9%
Peak to trough
ATR 14
0.05
6.49% of price
Beta (reported)
2.32
5Y monthly, from filing
Short interest
Shares short
3.12M
Prior 2.31M
Change vs prior
+35.0%
Shorts adding
% of float
2.11%
Normal
% of shares out
1.97%
Against total outstanding
Days to cover
1.7
Liquid
Float
145.87M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 1, 26 | Craig-Hallum | INITIATED | — | Buy |
| Jun 4, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Apr 24, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 26, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Jan 30, 26 | Morgan Stanley | DOWNGRADE | Overweight | Equal-Weight |
| Dec 2, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Nov 21, 25 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Sep 26, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Sep 15, 25 | HC Wainwright & Co. | INITIATED | — | Buy |
| Aug 28, 25 | Ladenburg Thalmann | INITIATED | — | Buy |
| Aug 14, 25 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Apr 15, 25 | Canaccord Genuity | INITIATED | — | Buy |
SEC filings
Proxy Statements
PRE 14A · 2026-08-14
Periodic Financial Reports
10-Q · 2026-08-10
Corporate Changes & Voting Matters
8-K · 2026-07-15
Corporate Changes & Voting Matters
8-K · 2026-06-11
Corporate Changes & Voting Matters
8-K · 2026-06-04
Corporate Changes & Voting Matters
8-K · 2026-05-12
Corporate Changes & Voting Matters
8-K · 2026-05-11
Proxy Statements
DEFA14A · 2026-04-24
Headlines
Fractyl Health to Host Virtual Commercial Strategy Day on Tuesday, September 1, 2026: The Potential Path to Commercializing Revita®, a Procedural Therapy for Post-GLP-1 Weight Maintenance
GlobeNewswire · 3d ago
Fractyl Health Eyes Q4 Revita Data, Launches Rejuva Gene Therapy Trial
MarketBeat · 9d ago
Fractyl Health, Inc. Common Stock Q2 2026 Earnings Call Summary
Moby · 12d ago
Fractyl Health Inc (GUTS) (Q2 2026) Earnings Call Highlights: Pivotal Data on Track and ...
GuruFocus.com · 12d ago
Fractyl Health Q2 Earnings Call Highlights
MarketBeat · 13d ago
Fractyl Health Reports Second Quarter 2026 Financial Results and Business Updates
GlobeNewswire · 13d ago
Fractyl Health to Report Second Quarter 2026 Financial Results and Provide Business Updates on August 10, 2026
GlobeNewswire · 20d ago
Fractyl Health to Participate in Upcoming Investor Events
GlobeNewswire · 32d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.